HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9.
May 22, 2024 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Alpha Tau Medical and maintained a price target of $9, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. suggests strong confidence in Alpha Tau Medical's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100